Companies MiniMed Group
MiniMed (MMED): executive pay, fiscal 2026
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me MiniMed Group’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
MiniMed Group's highest-paid named officer for fiscal year 2026, Executive Vice President, Chief Financial Officer Chad Spooner, was paid $7,066,593 · source
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chad Spooner | $519,231 | $970,000 | $4,885,460 | $647,908 | $0 | $0 | $43,994 | $7,066,593 |
| Executive Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Chad Spooner | $7,066,593 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
No outstanding equity awards are on file for this fiscal year.
Director compensation
No director compensation table is on file for fiscal year 2026.
Board fee structure and ownership guideline
| Annual cash retainer | $70,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | — |
Peer group, and who names MiniMed as a peer
Companies that benchmark against MMED
No companies currently name MMED as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2026
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Bausch + Lomb | 2025 | Brenton Saunders | $1,600,000 | $23,778,578 | $2,799,998 | $4,000,000 | $32,194,326 |
| 2 | Intuitive Surgical | 2025 | David Rosa | 858,750 | 18,674,872 | 0 | 1,373,859 | 20,997,480 |
| 3 | Solventum | 2025 | Bryan Hanson | 1,350,000 | 15,209,022 | 0 | 2,988,900 | 20,139,981 |
| 4 | Masimo | 2025 | Catherine Szyman | 850,048 | 16,388,693 | 1,399,998 | 1,130,000 | 19,797,140 |
| 5 | Align Technology | 2025 | Joseph Hogan | 1,400,000 | 16,556,872 | 0 | 1,220,100 | 19,193,988 |
| 6 | Insulet | 2025 | Ashley McEvoy | 729,808 | 12,958,850 | 2,999,913 | 2,031,562 | 18,858,968 |
| 7 | ResMed | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 8 | The Cooper Companies | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 9 | Hologic | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 10 | Exact Sciences | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 11 | Envista Holdings | 2025 | Paul Keel | 1,100,000 | 5,440,152 | 1,360,045 | 2,486,550 | 10,559,567 |
| 12 | Dolby Laboratories, Inc. | 2025 | Kevin Yeaman | 950,000 | 6,244,956 | 2,067,450 | 893,000 | 10,193,397 |
| 13 | Bio-Techne | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 14 | LivaNova | 2025 | Vladimir Makatsaria | 956,115 | 4,303,092 | 1,374,999 | 1,287,656 | 8,047,217 |
| 15 | DexCom | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 16 | Inspire Medical | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 17 | MiniMed Group | 2026 | Chad Spooner | 519,231 | 4,885,460 | 647,908 | 0 | 7,066,593 |
| 18 | Tandem Diabetes Care | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 19 | Teleflex | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 20 | ICU Medical | 2025 | Vivek Jain | 775,000 | 4,500,023 | 0 | 1,162,500 | 6,452,042 |
| 21 | Globus Medical | 2025 | Keith Pfeil | 479,467 | 0 | 2,982,347 | 783,000 | 4,400,159 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| MiniMed Group | not disclosed | not disclosed | not disclosed | not disclosed |
| Align Technology | 58.1% | MSU 70 · RSU 30 | Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite Index | Compensia, Inc. |
| Bausch + Lomb | 100% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pay Governance |
| Bio-Techne | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| DexCom | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Dolby Laboratories, Inc. | 94% | RSU 50 · PSU 25 · Options 25 | Yes — 3-Year Annualized TSR Dolby vs. S&P Midcap 400 Index | Compensia / FW Cook |
| Envista Holdings | 151% | PSU 60 · Options 20 · RSU 20 | No | Frederic W. Cook & Co, Inc. |
| Exact Sciences | 47% | PSU 60 · RSU 40 | No | Aon |
| Globus Medical | 102% | Options 100 | not disclosed | FW Cook |
| Hologic | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| ICU Medical | 150% | PSU 50 · RSU 50 | No | Compensia |
| Inspire Medical | 111.4% | PSU 50 · RSU 50 | No | Aon |
| Insulet | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| Intuitive Surgical | 115.2% | RSU 50 · PSU 50 | No | Aon |
| LivaNova | 122.4% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Masimo | not disclosed | not disclosed | not disclosed | FW Cook |
| ResMed | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Solventum | 123% | PSU 50 · RSU 50 | Yes — 3-year rTSR | Korn Ferry |
| Tandem Diabetes Care | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
| Teleflex | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
| The Cooper Companies | 100.9% | Options 50 · PSU 50 | No | Compensia |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 5 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2026 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Medtronic plc | Greater-than-10% holder | 2026-10-15 | D | 252,813,348 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (24 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Chad Spooner. DEF 14A, filed 2026-08-21. Section “Executive Compensation”. As printed: 7,066,593. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-08-21. Section “CEO Pay Ratio”. As printed: 5 : 1. View filing ↗
- Section 02, Medtronic plc 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Bausch + Lomb, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Bausch + Lomb's own proxy. As printed: 32,194,326. View filing ↗
- Intuitive Surgical, Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Intuitive Surgical's own proxy. As printed: 20,997,480. View filing ↗
- Solventum, Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Solventum's own proxy. As printed: 20,139,981. View filing ↗
- Masimo, Section 10b CEO total. 10-K/A, filed 2026-05-01. CEO total compensation as printed in Masimo's own proxy. As printed: 19,797,140. View filing ↗
- Align Technology, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Align Technology's own proxy. As printed: 19,193,988. View filing ↗
- Insulet, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Insulet's own proxy. As printed: 18,858,968. View filing ↗
- ResMed, Section 10b CEO total. DEF 14A, filed 2026-10-01. CEO total compensation as printed in ResMed's own proxy. As printed: 16,201,649. View filing ↗
- The Cooper Companies, Section 10b CEO total. DEF 14A, filed 2026-02-24. CEO total compensation as printed in The Cooper Companies's own proxy. As printed: 16,051,141. View filing ↗
- Hologic, Section 10b CEO total. DEF 14A, filed 2025-01-16. CEO total compensation as printed in Hologic's own proxy. As printed: 15,819,261. View filing ↗
- Exact Sciences, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences's own proxy. As printed: 15,539,378. View filing ↗
- Envista Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Envista Holdings's own proxy. As printed: 10,559,567. View filing ↗
- Dolby Laboratories, Inc., Section 10b CEO total. DEF 14A, filed 2025-12-16. CEO total compensation as printed in Dolby Laboratories, Inc.'s own proxy. As printed: 10,193,397. View filing ↗
- Bio-Techne, Section 10b CEO total. DEF 14A, filed 2025-09-19. CEO total compensation as printed in Bio-Techne's own proxy. As printed: 8,151,181. View filing ↗
- LivaNova, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in LivaNova's own proxy. As printed: 8,047,217. View filing ↗
- DexCom, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in DexCom's own proxy. As printed: 7,985,960. View filing ↗
- Inspire Medical, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Inspire Medical's own proxy. As printed: 7,711,784. View filing ↗
- MiniMed Group (subject), Section 10b CEO total. DEF 14A, filed 2026-08-21. CEO total compensation as printed in MiniMed Group's own proxy. As printed: 7,066,593. View filing ↗
- Tandem Diabetes Care, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care's own proxy. As printed: 6,858,503. View filing ↗
- Teleflex, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Teleflex's own proxy. As printed: 6,732,419. View filing ↗
- ICU Medical, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in ICU Medical's own proxy. As printed: 6,452,042. View filing ↗
- Globus Medical, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Globus Medical's own proxy. As printed: 4,400,159. View filing ↗